Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

NCT07747506 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

2

Enrollment

INDUSTRY

Sponsor class

Conditions

Low Grade Ovarian Serous Adenocarcinoma
Ovarian Cancer

Interventions

DRUG: avutometinib + defactininb combination

Sponsor

Verastem, Inc.